Here are the top 5 biosimilar articles for the week of July 27, 2020.
Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of July 27, 2020.
Number 5: As Samsung Biologics’ bioreactor facilities are expected to reach full utilization by 2022, the company said it will construct a fourth plant and a bio campus, according to industry reports.
Number 4: The Center for Biosimilars® spoke with Adrian van den Hoven, director general of Medicines for Europe, and Diogo Piedade, market access manager for Medicines for Europe, about their scorecard report for biosimilar access in European markets.
Number 3: While many countries are in lockdown due to the coronavirus disease 2019 (COVID-19) pandemic, pharmaceutical chains like Samsung Bioepis have ensured supply continuity and flexibility to swiftly respond to market changes by regionalizing supply chain activities to provide near-market manufacturing.
Number 2: Biosimilar misinformation takes many forms, some of it institutionalized in the form of word usage and some of it deliberately disparaging, 2 executives of Sandoz and Boehringer Ingelheim contend.
Number 1: President Trump signed 4 executive orders that would lower prices of prescriptions medications including insulin products and cancer medicines.
To read all of these articles and more, visit centerforbiosimilars.com.